title: Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data.
abstract: Adalimumab is a fully human monoclonal antibody directed against tumor necrosis factor (TNF)-alpha, which is effective for the treatment of psoriasis and psoriatic arthritis (PsA). The aim of this study is to determine whether the response of psoriasis to adalimumab treatment might be influenced by certain particular factors, such as body mass index (BMI), history of biologic therapy, blood hypertension and metabolic comorbidities. For this reason, an exploratory analysis was conducted on 144 patients with psoriasis and concomitant PsA treated with adalimumab 40 mg every other week, evaluating the influence of such factors on the Psoriasis Area and Severity Index (PASI) response rate at week 12. Our preliminary results suggest that the response rate at week 12, in terms of both PASI-50 and PASI-75, appeared to be independent of the presence of hypertension and/or metabolic comorbidities. The PASI-50 response was observed more frequently in patients with BMI less than 30 as compared to obese patients (79% vs 58%, p = 0.02). Previous use of anti-TNF biologics did not appear to affect per se the rate of responders, although it was associated with a lower PASI-75 rate among responders.
authors.affiliation: 2nd Dermatology Clinic, University of Bari, Bari Italy.
authors.forename: N
authors.initials: N
authors.lastname: Cassano
authors.forename: A
authors.initials: A
authors.lastname: Galluccio
authors.forename: C
authors.initials: C
authors.lastname: De Simone
authors.forename: F
authors.initials: F
authors.lastname: Loconsole
authors.forename: S D
authors.initials: SD
authors.lastname: Massimino
authors.forename: A
authors.initials: A
authors.lastname: Plumari
authors.forename: S
authors.initials: S
authors.lastname: Dattola
authors.forename: A
authors.initials: A
authors.lastname: Puglisi Guerra
authors.forename: L
authors.initials: L
authors.lastname: Donato
authors.forename: F
authors.initials: F
authors.lastname: Cantoresi
authors.forename: O
authors.initials: O
authors.lastname: De Pita
authors.forename: G
authors.initials: G
authors.lastname: Fenizi
authors.forename: V
authors.initials: V
authors.lastname: Altamura
authors.forename: M
authors.initials: M
authors.lastname: Congedo
authors.forename: R
authors.initials: R
authors.lastname: Pellicano
authors.forename: G A
authors.initials: GA
authors.lastname: Vena
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015535:Arthritis, Psoriatic / Q000150:complications / Q000473:pathology / Q000628:therapy; D001688:Biological Products / Q000627:therapeutic use; D015992:Body Mass Index; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab